GPT and metabolic dysfunction-associated steatohepatitis: A meta-analysis of 7 trials showed that treatment with 10 mg dose dapagliflozin compared to the placebo or control group in patients with NASH (image-based diagnosis) significantly lowered ALT (weighted mean difference (WMD): − 6.62U/L; 95%CI: − 12.66, − 0.58; p = 0.03) and AST levels (WMD: − 4.20U/L; 95%CI: − 7.92,-0.47; p = 0.03).